Intraoperative radiotherapy-containing multidisciplinary management of trunk-wall soft-tissue sarcomas

• DOI: 10.1007/s12094-014-1157-y
• Publication Date: 2014-01-31T20:41:59Z
• Authors: C. V. Sole; F. A. Calvo; M. Cambeiro; A. Polo; A. Montero; R. Hernanz; C. Gonzalez; M. Cuervo; D. Perez; M. S. Julian; R. Martinez-Monge
• Keywords: Adult; Male; Radiotherapy; Sarcoma; Kaplan-Meier Estimate; Middle Aged; Combined Modality Therapy; Disease-Free Survival; 3. Good health; Intraoperative Period; 03 medical and health sciences; 0302 clinical medicine; Ciencias Biomédicas; Humans; Female; Aged; Proportional Hazards Models

A joint analysis of data from centers within the intraoperative radiotherapy (IORT)-Spanish cooperative initiative was performed to investigate the main contributions of IORT to the multidisciplinary treatment of trunk-wall soft-tissue sarcoma (TW-STS).Patients with a histologic diagnosis of TW-STS (primary tumor 53 %; locally recurrent 47 %) with absence of distant metastases, undergoing surgery with radical intent and IORT (median dose 12.5 Gy) were considered eligible for participation in this study. In addition, all primary tumors received external-beam radiotherapy (median dose 50 Gy).From 1986 to 2012, a total of 68 patients were analyzed in the study from three Spanish institutions. With a median follow-up time of 53 months (range 4-316), 5-year local control (LC) was 58 %. Five-year IORT in-field control, disease-free survival (DFS) and overall survival were 70, 45 and 51 %, respectively. On multivariate analysis, only microscopically involved margin (R1) resection status retained significance in relation to LC (HR 3.97, p < 0.001). In regard to IORT in field control, incomplete resection (HR 3.23, p = 0.008) and recurrent disease status (HR 2.52, p = 0.04) retained a significant association in multivariate analysis.From this joint analysis emerges the fact that margin and disease status influences local and central control, but DFS remains modest, given the high risk of distant metastases. Intensified local treatment needs to be tested in the context of more efficient concurrent, neo-, and adjuvant systemic therapy.